

## REMARKS

Applicants have amended the specification to correct some inadvertent typographical errors found in Scheme 3 and on page 21 of the specification. In particular, in the formula of the last compound in Scheme 3 on page 19, the HO- group at C-1 position has been changed to DMSO-. This amendment has also been made in the formula of the first compound in Scheme 3 (continued) on page 20. This is a typographical error on applicants' part and support for this change can be found on page 31, "Synthesis of baccatin derivative 4." where the group shown at the C-1 position is  $\text{Me}_2\text{HSiO-}$ , (which is identical to DMSO-).

Additionally, the formula (i.e.,  $\text{R}^1\text{-C(O)Cl}$ ) in line 14 on page 21 was incorrect, and therefore has been deleted.


No new matter has been added. The amendment addresses formal matters only and does not effect the merits of the case. It is respectfully requested that this amendment be considered and entered prior to issuance of a patent corresponding to the present application.

If any matter should remain outstanding after the Examiner has had an opportunity to review the above Remarks, the Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-6457

  
Henry H. Gu  
Agent for Applicants  
Reg. No. 55,227

Date: February 11, 2005